Drug Search Results
More Filters [+]

CLS-003

Alternative Names: cls-003, cls003, cls 003
Latest Update: 2019-03-20
Latest Update Note: Clinical Trial Update

Product Description

For healthy patients with cutaneous warts

Mechanisms of Action: Sodium Potassium ATPase Inhibitor,NKCC Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Maruho
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CLS-003

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Warts

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CLS003-CO-PR-003

P2

Terminated

Warts

2018-10-30

30%

CLS003-CO-PR-002

P2

Completed

Warts

2015-08-01

CLS003-CO-PR-001

P2

Completed

Warts

2014-04-01

Recent News Events

Date

Type

Title